Multivariable analyses of OS of CA-AML patients
| Patient set . | . | Variables . | HR . | 95% CI . | P . |
|---|---|---|---|---|---|
| USA-set-I (n = 33) | miR-181a (high vs low) | 0.70 | 0.48-1.02 | .06 | |
| miR-181b (high vs low) | 0.65 | 0.43-0.98 | .04 | ||
| miR-181c (high vs low) | 0.79 | 0.57-1.09 | .15 | ||
| miR-181d (high vs low) | 0.74 | 0.49-1.11 | .15 | ||
| Age, years ( ≥ 60 vs < 60) | 3.20 | 0.98-10.45 | .05 | ||
| t(11q23) vs others | 8.17 | 1.65-40.45 | .01 | ||
| t(15;17) vs others | 0.12 | 0.02-0.61 | .01 | ||
| USA-set-II (n = 53) | miR-181a (high vs low) | 0.49 | 0.23-1.05 | .07 | |
| miR-181b (high vs low) | 0.41 | 0.20-0.85 | .02 | ||
| miR-181c (high vs low) | 0.56 | 0.29-1.09 | .09 | ||
| miR-181d (high vs low) | 0.49 | 0.23-1.03 | .06 | ||
| Age, years ( ≥ 60 vs < 60) | 2.68 | 1.30-5.55 | .008 | ||
| t(11q23) vs others | 3.03 | 1.34-6.87 | .007 | ||
| Training sets (n = 183) | USA-set-II-35S (n = 35) | 4-gene signature (high vs low) | 4.81 | 1.52-15.29 | .008 |
| 9-gene signature (high vs low) | 6.21 | 1.95-19.80 | .002 | ||
| Age (each 10-year increase) | 1.46 | 1.20-1.80 | < .001 | ||
| USA-set-III (n = 87) | 4-gene signature (high vs low) | 2.66 | 1.03-6.88 | .04 | |
| 9-gene signature (high vs low) | 1.80 | 0.63-5.15 | .27 | ||
| PB blasts (high vs low) | 5.66 | 1.87-17.16 | .002 | ||
| t(15;17) vs others | 0.38 | 0.15-0.97 | .04 | ||
| Germany Set-I (n = 106) | 4-gene signature (high vs low) | 2.62 | 1.04-6.58 | .04 | |
| 9-gene signature (high vs low) | 1.95 | 0.84-4.55 | .12 | ||
| del(7q)/−7 vs others | 4.82 | 1.57-14.81 | .006 | ||
| Complex vs others | 11.73 | 2.62-52.49 | .001 | ||
| log2(WBC) (each 2-unit increase) | 2.94 | 1.37-6.31 | .006 | ||
| Validation set (n = 271) | Netherlands-set-I (n = 271) | 4-gene signature (high vs low) | 1.66 | 1.03-2.70 | .04 |
| 9-gene signature (high vs low) | 1.54 | 1.00-2.37 | .05 | ||
| Age (each 10-year increase) | 3.06 | 1.17-7.99 | .02 | ||
| Complex vs others | 2.03 | 1.25-3.29 | .004 | ||
| 7q vs others | 2.23 | 1.42-3.51 | .0005 | ||
| 3q vs others | 1.76 | 1.00-3.11 | .05 | ||
| t(8;21) vs others | 0.37 | 0.19-0.71 | .003 | ||
| inv(16) vs others | 0.41 | 0.21-0.79 | .008 | ||
| CBF AML vs others | 0.41 | 0.21-0.79 | .008 | ||
| FLT3-ITD vs others | 1.74 | 1.09-2.79 | .02 | ||
| FLT3-TKD vs others | 0.44 | 0.21-0.90 | .02 | ||
| CEBPA mutation vs wild-type | 0.26 | 0.08-0.85 | .03 |
| Patient set . | . | Variables . | HR . | 95% CI . | P . |
|---|---|---|---|---|---|
| USA-set-I (n = 33) | miR-181a (high vs low) | 0.70 | 0.48-1.02 | .06 | |
| miR-181b (high vs low) | 0.65 | 0.43-0.98 | .04 | ||
| miR-181c (high vs low) | 0.79 | 0.57-1.09 | .15 | ||
| miR-181d (high vs low) | 0.74 | 0.49-1.11 | .15 | ||
| Age, years ( ≥ 60 vs < 60) | 3.20 | 0.98-10.45 | .05 | ||
| t(11q23) vs others | 8.17 | 1.65-40.45 | .01 | ||
| t(15;17) vs others | 0.12 | 0.02-0.61 | .01 | ||
| USA-set-II (n = 53) | miR-181a (high vs low) | 0.49 | 0.23-1.05 | .07 | |
| miR-181b (high vs low) | 0.41 | 0.20-0.85 | .02 | ||
| miR-181c (high vs low) | 0.56 | 0.29-1.09 | .09 | ||
| miR-181d (high vs low) | 0.49 | 0.23-1.03 | .06 | ||
| Age, years ( ≥ 60 vs < 60) | 2.68 | 1.30-5.55 | .008 | ||
| t(11q23) vs others | 3.03 | 1.34-6.87 | .007 | ||
| Training sets (n = 183) | USA-set-II-35S (n = 35) | 4-gene signature (high vs low) | 4.81 | 1.52-15.29 | .008 |
| 9-gene signature (high vs low) | 6.21 | 1.95-19.80 | .002 | ||
| Age (each 10-year increase) | 1.46 | 1.20-1.80 | < .001 | ||
| USA-set-III (n = 87) | 4-gene signature (high vs low) | 2.66 | 1.03-6.88 | .04 | |
| 9-gene signature (high vs low) | 1.80 | 0.63-5.15 | .27 | ||
| PB blasts (high vs low) | 5.66 | 1.87-17.16 | .002 | ||
| t(15;17) vs others | 0.38 | 0.15-0.97 | .04 | ||
| Germany Set-I (n = 106) | 4-gene signature (high vs low) | 2.62 | 1.04-6.58 | .04 | |
| 9-gene signature (high vs low) | 1.95 | 0.84-4.55 | .12 | ||
| del(7q)/−7 vs others | 4.82 | 1.57-14.81 | .006 | ||
| Complex vs others | 11.73 | 2.62-52.49 | .001 | ||
| log2(WBC) (each 2-unit increase) | 2.94 | 1.37-6.31 | .006 | ||
| Validation set (n = 271) | Netherlands-set-I (n = 271) | 4-gene signature (high vs low) | 1.66 | 1.03-2.70 | .04 |
| 9-gene signature (high vs low) | 1.54 | 1.00-2.37 | .05 | ||
| Age (each 10-year increase) | 3.06 | 1.17-7.99 | .02 | ||
| Complex vs others | 2.03 | 1.25-3.29 | .004 | ||
| 7q vs others | 2.23 | 1.42-3.51 | .0005 | ||
| 3q vs others | 1.76 | 1.00-3.11 | .05 | ||
| t(8;21) vs others | 0.37 | 0.19-0.71 | .003 | ||
| inv(16) vs others | 0.41 | 0.21-0.79 | .008 | ||
| CBF AML vs others | 0.41 | 0.21-0.79 | .008 | ||
| FLT3-ITD vs others | 1.74 | 1.09-2.79 | .02 | ||
| FLT3-TKD vs others | 0.44 | 0.21-0.90 | .02 | ||
| CEBPA mutation vs wild-type | 0.26 | 0.08-0.85 | .03 |
Variables for which P < .1 in univariable models (supplemental Tables 1 or 4) were included in multivariable analyses. Hazard ratios (HR) > 1 or < 1 indicate, respectively, a higher or lower risk of an event (death) for higher values of continuous variables and for the first category listed for categorical variables in OS models.